Drug intelligence / Profile preview

AD108

Development stage: Unknown
Lead developer: AIDEA PHARMA
Modality: Small Molecules
Administration: Subcutaneous

Overview

AD108 is an innovative small molecule neuroprotective agent being developed by Jiangsu Aidi Pharmaceutical (also known as Aidea Pharma) for the treatment of acute ischemic stroke. As a Class 1 innovative drug in China, it is designed to mitigate the neuronal damage that occurs during the ischemic cascade following a stroke event, with the objective of improving neurological functional recovery and reducing long-term disability. The compound is currently in Phase 1 clinical development, where its safety, tolerability, and pharmacokinetic profile are being evaluated in human subjects.

Beyond the preview

Go deeper on AD108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD108.

Explore the full profile